Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | S100B | P04271 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TERT | O14746 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11886393 | 0.96 | MAPT (0.44) | SNCAMAPTMEN1KMT2AGAA | |
| SCHEMBL5724663 | 0.95 | ALDH1A1 (0.47) | SNCAMAPTMEN1KMT2AGAA | |
| SCHEMBL12449201 | 0.89 | NOX1 (0.53) | SNCAMAPTMEN1KMT2AGAA | |
| SCHEMBL9560163 | 0.78 | NOX1 (0.49) | SNCAMAPTMEN1KMT2AGAA | |
| SCHEMBL12272774 | 0.76 | ALDH1A1 (0.34) | MAPTMEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL16004687 | 0.74 | MAPT (0.39) | MAPTMEN1KMT2AALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL13386452 | 0.73 | MAPT (0.39) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL12272572 | 0.73 | ALDH1A1 (0.37) | MAPTMEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL16285333 | 0.73 | ALDH1A1 (0.53) | MAPTMEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL13354346 | 0.73 | SNCA (0.41) | SNCAMAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | Prosetta Antiviral, Inc. | 2017-06-01 | — | — | US | disclosed |
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | Prosetta Antiviral, Inc. | 2017-06-01 | — | — | US | disclosed |
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | Prosetta Antiviral, Inc. | 2017-06-01 | — | — | US | disclosed |
| US-9382221-B2 | Compounds, compositions, and methods for treating alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382221-B2 | Compounds, compositions, and methods for treating alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382221-B2 | Compounds, compositions, and methods for treating alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140315897-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Prosetta Antiviral, Inc. | 2014-10-23 | — | — | US | disclosed |
| US-20140315897-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Prosetta Antiviral, Inc. | 2014-10-23 | — | — | US | disclosed |
| US-20140315897-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Prosetta Antiviral, Inc. | 2014-10-23 | — | — | US | disclosed |
| US-8796448-B1 | Compounds, compositions, and methods for treating Alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796448-B1 | Compounds, compositions, and methods for treating Alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796448-B1 | Compounds, compositions, and methods for treating Alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2014-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | PSEN1, APP, PSEN2 | SNCA 27/4885MAPT 11/4885MEN1 1540/4885 |
| US-20140315897-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN1, APP, PSEN2 | SNCA 27/4885MAPT 11/4885MEN1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.